Ingeborg E. van Zeggeren

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

Alexander P. J. Vlaar, Sanne de Bruin, Matthias H. Busch et al. · The Lancet Rheumatology · 2020 · 198 citations · Full text

Clinical Infectious Disease, Covid-19 Pandemic, Immunology +7

Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Alexander P. J. Vlaar, Martin Witzenrath, Pieter van Paassen et al. · The Lancet Respiratory Medicine · 2022 · 131 citations · Full text

Critical Care Medicine, Clinical Infectious Disease, Anti-c5a Antibody +6

Viral Metagenomics on Cerebrospinal Fluid

Arthur W. D. Edridge, Martin Deijs, Ingeborg E. van Zeggeren et al. · Genes · 2019 · 49 citations · Full text

Sex steroid hormones are associated with mortality in COVID-19 patients

Ingeborg E. van Zeggeren, Anita Boelen, Diederik van de Beek et al. · Medicine · 2021 · 26 citations · Full text

Reproductive Health, Gynecology, Free Testosterone +24

Diagnostic accuracy of inflammatory markers in adults with suspected central nervous system infections

Sabine E. Olie, Steven L. Staal, Liora ter Horst et al. · Journal of Infection · 2024 · 20 citations · Full text